Back to top

Cantor Fitzgerald Remains a Buy on Viking Therapeutics (VKTX)

Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Viking Therapeutics today and set a price target of $100.00. Seedhouse covers...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viking Therapeutics, Inc. (VKTX)